No Data
No Data
Cansino Biotech (06185) announced annual results, losses attributable to shareholders of 1,483 billion yuan, an increase of 63.04% year-on-year
Cansino Biotech (06185) announced its annual results for the year ended December 31, 2023. The group achieved...
康希諾生物:截至2023年12月31日止的年度業績公告
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug
Cansino Biologics (HKG:6185) has officially commenced the phase III clinical trial for the Absorbed Tetanus Vaccine, with the formal enrollment of the first trial patient, according to a Wednesday Hon
Cansino Biotech (06185.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Glonghui, March 15, 丨 Cansino Biotech (06185.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to recommend the payment of an annual dividend (if any).
CANSINOBIO: NOTICE OF BOARD MEETING
Cansino (688185.SH): Belcher has a strong defense against the company in filing a lawsuit against the company
Cansino (688185.SH) issued an announcement. The company recently received the 3ª Vara Civel d...
No Data